Adam Loose
Psychiatric/Mental Health · Lexington, KYNPI 1295216091
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Alkermes, Inc. at 52.7% of the total. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 354 payments — averaging $124.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$23K
- E.r. Squibb & Sons, L.L.C.$17K
- Johnson & Johnson$903
- Otsuka America Pharmaceutical, Inc.$805
- Teva Pharmaceuticals USA, Inc.$567
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$517
- plus $814 from 8 others
What the payments were for
- Consulting fees$13,45731%
- Speaking & faculty fees$16,91038%
- Travel & lodging$6,63015%
- Food & beverage$6,77915%
- Education$3051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 106 | $23,250 |
| E.r. Squibb & Sons, L.L.C. | 50 | $17,224 |
| Johnson & Johnson | 42 | $903 |
| Otsuka America Pharmaceutical, Inc. | 43 | $805 |
| Teva Pharmaceuticals USA, Inc. | 28 | $567 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $517 |
| Lundbeck LLC | 22 | $386 |
| AbbVie | 8 | $178 |
| Neurocrine Biosciences, Inc. | 6 | $93 |
| Indivior Inc. | 4 | $57 |
| Sunovion Pharmaceuticals Inc. | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$49,544
- LYBALVI$41,376
- ARISTADA INITIO$6,498
- COBENFY$1,528
- VRAYLAR$129
How this compares
$44,080 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $36,066 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $17,137 |
| Divalproex Sodium | 24 | $809 |
| Hydroxyzine Pamoate | 19 | $204 |
| Buspirone Hcl | 11 | $181 |
| Mirtazapine | 13 | $108 |
| Trazodone Hcl | 21 | $104 |
| Olanzapine | 11 | $103 |
| Sertraline Hcl | 14 | $40 |
| Clonidine Hcl | 11 | $16 |
| Fluoxetine Hcl | 13 | $16 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $903 | $36,06612 claims |
| Alkermes, Inc.Lybalvi | $23,250 | $17,13711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Lexington
- Lauren WilliamsLexington$40K
- Laura ThomsonLexington$25K
- Laura WeddleLexington$15K
- Latoya LeeLexington$12K
- Isabel JonesLexington$9K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.